Our grit and science drive solutions for patients. Every day, we strive to advance our pipeline of innovative therapeutic candidates to treat rare diseases. We are targeting the CRCX4 pathway, one of the most important chemokine pathways, in an effort to treat people with rare immune system disorders.
Aberrant functioning of CXCR4 is associated with certain PI diseases. X4 has now completed enrollment in its pivotal Phase 3 clinical trial for its lead candidate, mavorixafor, in patients with WHIM syndrome.
X4 is developing novel, oral medicines designed to treat a range of rare diseases, including primary immunodeficiency diseases and certain rare cancers, such as lymphomas.
January 19, 2022
X4 Pharmaceuticals to Present at B. Riley Securities...
January 05, 2022
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq...
X4 Pharmaceuticals does not review or control the content on the website to which this hyperlink connects and this hyperlink does not constitute an endorsement by X4 Pharmaceuticals of the content of any non-X4 Pharmaceuticals website.